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Abstract
The DNA polymerase-gamma (POLG) gene, which encodes the catalytic subunit of enzyme responsible for directing
mitochondrial DNA replication in humans, contains a polyglutamine tract encoded by CAG repeats of varying length. The
length of the CAG repeat has been associated with the risk of testicular cancer, and other genomic variants that impact
mitochondrial function have been linked to breast cancer risk in African-American (AA) women. We evaluated the potential
role of germline POLG-CAG repeat variants in breast cancer risk in a sample of AA women (100 cases and 100 age-matched
controls) who participated in the Women’s Circle of Health Study, an ongoing multi-institutional, case-control study of
breast cancer. Genotyping was done by fragment analysis in a blinded manner. Results from this small study suggest the
possibility of an increased risk of breast cancer in women with minor CAG repeat variants of POLG, but no statistically
significant differences in CAG repeat length were observed between cases and controls (multivariate-adjusted odds ratio
1.74; 95% CI, 0.49–6.21). Our study suggests that POLG-CAG repeat length is a potential risk factor for breast cancer that
needs to be explored in larger population-based studies.
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Introduction
Despite the overall higher incidence of breast cancer in
European-American (EA) women as compared to African-
American (AA) women, AA women are more likely to be
diagnosed with breast cancer before age 40 and to have tumors
with aggressive pathological characteristics, including high tumor
grade, lack of expression of estrogen and progesterone receptors
(ER, PR) and HER2 (triple-negative breast cancers), and
additional features of basal-like breast cancer (ER2/PR2/
HER22/cy5/6+/EGFR+) [1]. Triple-negative and basal-like
breast cancers are recognized to be associated with a considerably
poorer prognosis than other breast cancer subtypes [2]. Although
the role of genetic factors, including polymorphisms in the
BRCA1, BRCA2, ATM, CHEK2, p53, PTEN, NBS1, RAD50,
BRIP1, and PALB2 genes have been extensively studied in breast
cancer in EA populations [3], there are few studies of the role of
common variants in nuclear gene(s) related to mitochondrial
function in the etiology of breast cancer in AA women.
A recent study demonstrated that tumor-cell mitochondrial
DNA copy (mtDNA) number correlates with tumor progression as
well as patient prognosis and disease-free survival in breast cancer
[4]. Cellular mtDNA copy number (or content) is controlled by the
nuclear-encoded POLG gene encoding the only known mtDNA
polymerase (polymerase-gamma) in humans. Our previous
research suggests that mutations in the POLG gene may result in
depletion of mtDNA and confer breast cancer phenotype [5].
Human POLG consists of an exonuclease domain with three
exonuclease motifs, I, II and III, and a polymerase domain with
three polymerase motifs, A, B and C, along with an intervening
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responsible for the proof-reading activity of the encoded enzyme,
harbors a CAG repeat region in exon 2. The contraction of CAG
repeats in POLG affects its expression [7], and an expanded CAG
repeat sequence seems to confer toxic functions on the protein
through protein-protein interactions [8]. The CAG repeat
polymorphism has been studied in several diseases, including
male infertility and neurodegeneration [9–11]. An association of
the POLG-CAG repeat expansion with testicular cancer has also
been reported [12]. Previous studies have also suggested that
variation in the number of CAG repeats in androgen- and
estrogen-receptor genes influence the risk of breast cancer [13].
However, the significance of the CAG repeat polymorphism of
POLG in breast cancer has not been investigated. The purpose of
this study was to evaluate the association of POLG CAG repeat
length with breast cancer risk in the Women’s Circle of Health
Study (WCHS), an epidemiological case-control study of breast
cancer in AA and EA women.
Materials and Methods
Study subjects
The data and samples from 100 AA women with breast cancer
and 100 age-matched AA controls for this study were obtained
from the Women’s Circle of Health Study (WCHS), a case-control
study specifically designed to investigate risk factors for early,
aggressive breast cancer in AA women. The WCHS has been
previously described [14]. Briefly, women with incident, primary
breast cancer were identified through both hospital-based case
ascertainment at hospitals in the New York City area and
population-based case ascertainment in seven counties in northern
New Jersey through the New Jersey State Cancer Registry, a
National Cancer Institute Surveillance, Epidemiology, and End
Results (SEER) registry. Controls without breast cancer were
identified by random-digit dialing and matched to cases by
telephone prefixes and 5-year age intervals. All study participants
completed an in-person, structured interview to obtain informa-
tion about lifestyle, reproductive, and medical histories, demo-
graphics and other variables; AA race was determined by self-
report. Participants provided either a blood or saliva sample at
enrollment. Body mass index (BMI) was assessed by measuring
height and weight at the interview and was calculated as weight in
kilograms (kg) divided by height in meters squared (m
2). All study
subjects provided written informed consent for the study and use
of biospecimens, and the study was approved by the Institutional
Review Boards at Mount Sinai School of Medicine (MSSM)
(coordinating site for NY enrollment and NYC controls), the local
NYC hospital (for cases), The Cancer Institute of New Jersey
(coordinating site for NJ enrollments) as well as at Roswell Park
Cancer Institute IRB approval number I-120807.
DNA isolation and PCR
Genomic DNA was extracted from whole blood and evaluated
for purity and concentration using a Nanodrop UV spectropho-
tometer and quantified on a spectrofluorometer (Gemini XS
SPECTRAmax, Molecular Devices, Sunnyvale, CA, USA) using
the PicoGreen dsDNA quantification kit, as per the manufactur-
er’s instructions (Invitrogen, Carlsbad, CA, USA).. Double-
stranded DNA was quantitated using a PicoGreen-based fluoro-
metric assay. Primers (POLG_F: 6FAM-tggatgtccaatgggttgtgc and
POLG_R: aagccaggtgttctgactcc) were designed to amplify a 275-bp
fragment encompassing CAG repeats present in exon 2 of POLG1.
The amplification was carried out in a 25 ul reaction containing
approximately 50 ng of template DNA, 0.6 uM of both forward
and reverse primers, and 0.5 ul AccuPrime
TM Taq DNA
polymerase (Invitrogen, USA) using a TECHNE TC-412
(9660.2 ml) thermocycler (MIDSCI, USA). The PCR conditions
were as follows: initial denaturation at 94uC for 4 min in 26
amplification cycles at 94uC for 10 sec, annealing at 61uC for
30 sec and 68uC for 40 sec, followed by a final extension step at
68uC for 5 min.
Genotyping assays
Fluorescently labeled fragments generated by PCR were
analyzed on ABI PRISM 3130XL (Applied biosystems, USA),
according to the DNA fragment analysis protocol. DNA fragment
data were collected and then visualized using GeneMapperH
software. The data containing the genomic location (peak size) for
all samples were exported as delimited text files and blindly
analyzed for the number of CAG repeats in each sample. Assay
reproducibility was tested using multiple runs of both positive and
negative samples with different CAG repeat variants.
Statistical Analysis
Differences between categorical variables were assessed with the
chi-square test, and continuous variables were compared using
Student’s t-test. All statistical tests were two-sided. Age at
menarche and the number of children were divided into tertiles
using cut-points based on the distribution of these variables among
controls. Age at first pregnancy was categorized as nulliparous,
#19, 20–24, 25–29, or $30. Menopausal status at the time of
cancer diagnosis was determined during the interview and
categorized as premenopausal, perimenopausal, or postmenopaus-
al. Crude and multivariate unconditional logistic regression
models adjusted for age, age at menarche, age at first full-term
pregnancy, menopausal status (menopausal, perimenopausal,
postmenopausal), first-degree family history of breast cancer
(yes/no) and BMI were used to calculate odds ratios (OR) and
corresponding 95% confidence intervals (CI) as a measure of
association between CAG repeats of mitochondrial DNA POLG
and breast cancer risk. All statistical analyses were computed with
SAS 9.2 (SAS Institute, Cary, NC, USA).
Results
The CAG fragment analysis was done in a blinded manner and
repeat length was carefully assigned based on the peak size. After
the initial observation, we eliminated 12 samples because they
showed poor signal due to inadequate DNA. In this subset of the
WCHS, there were no statistically significant differences between
cases and controls with respect to age at menarche, age at first
pregnancy, number of children, menopausal status, and family
history of breast cancer (Table 1). We identified 7 breast cancer
cases (7%) and 6 controls (6%) in which the common 10/10
POLG-CAG repeat was absent. The common 10/10 CAG repeat
occurred in 52 cases (55%) and 56 controls (60%); heterozygous
10/non-10 CAG repeats were observed in 36 cases (38%) and 31
controls (33%) (Table 2). The representative CAG repeat
contraction and expansion variants are shown as electrophero-
grams (Figure 1).
Compared with 10/10 repeats, the crude odds ratios (ORs) for
10/11, 10/12 repeats, and all other repeats were 1.16 (95% CI,
0.58–2.32), 0.93 (95% CI, 0.36–2.35), and 1.31 (95% CI, 0.46–
3.76), respectively (Table 1). After adjustment for age, age at
menarche, age at first full-term pregnancy, menopausal status,
first-degree family history of breast cancer, and BMI, the adjusted
ORs for 10/11 and 10/12 repeats were 1.15 (95% CI, 0.50–2.63)
and 1.25 (95% CI, 0.45–3.46), respectively. In the case of CAG
POLG and Breast Cancer
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increased risk of breast cancer, but no statistically significant
difference was observed in the frequency of CAG repeats between
cases and controls (OR 1.74; 95% CI, 0.49–6.21, Table 2).
Discussion
Mitochondrial POLG is the only polymerase known to be
involved in human mitochondrial DNA replication. POLG
contains CAG trinucleotide repeats in the coding region, and
CAG repeat sequences are described to be highly unstable, leading
to expansion or contraction of the repeat sequences [8]. In a recent
study of the POLG gene, we reported the CAG repeat expansion
occurs in 20% of breast cancer patients [5]. This pilot study
suggests the possibility of an association between altered POLG-
CAG repeat-length and an increased risk of breast cancer in AA
women.
The presence of expanded or contracted CAG repeats has been
linked with several diseases, including the human polyglutamine
diseases [8]. Other epidemiologic studies have shown either a
positive or negative correlation of CAG repeats with sporadic
breast cancer, and one study reported an inverse correlation
between POLG-CAG repeat length (r=20.81) and the age of
onset of disease in Friedreich’s Ataxia (FRDA) patients [13]. In
another study dealing with myotonic dystrophy, no significant
difference in the frequency of CAG repeats was seen between cases
Table 1. Selected characteristics of Cases and Controls in WCHS with POLG-CAG repeat polymorphism.
Characteristic
Cases (n=95)
n( % )
Controls (n=93)
n( % ) p
1
POLG 0.75
10/10 52 (54.7) 56 (60.2)
10/not 10 36 (37.9) 31 (33.3)
Not 10/not 10 7 (7.4) 6 (6.5)
Age at menarche 0.68
#12 50 (53.2) 44 (47.3)
12.5–13 20 (21.3) 24 (25.8)
13.5+ 24 (25.5) 25 (26.9)
Age at first pregnancy 0.95
Nulliparous 20 (21.1) 22 (26.7)
#19 23 (24.2) 19 (20.4)
20–24 26 (27.4) 25 (26.9)
25–29 16 (16.8) 15 (16.1)
30+ 10 (10.5) 12 (12.9)
Number of children 0.86
0–1 42 (44.2) 42 (45.2)
2–3 37 (39.0) 38 (40.9)
4+ 16 (16.8) 13 (14.0)
Menopausal Status 0.84
Premenopausal 35 (42.2) 34 (39.1)
Perimenopausal 19 (22.9) 23 (26.4)
Postmenopausal 31 (36.5) 31 (35.2)
First degree relative with breast cancer 0.57
No 80 (84.2) 81 (87.1)
Yes 15 (15.8) 12 (12.9)
Mean (Min-Max) Mean (Min-Max) p
2
Age 50.4 (29–65) 50.0 (30–65) 0.78
BMI 31.4 (17.9–50.4) 31.6 (19.7–66.7) 0.85
1Chi-square test.
2t-test.
doi:10.1371/journal.pone.0029548.t001
Table 2. Odd ratios of POLG-CAG repeat polymorphism in
WCHS.
Crude OR
(95% CI)
Adjusted
OR
1 (95% CI)
POLG
10/10 1.0 (ref) 1.0 (ref)
10/not 10 1.3 (0.68–2.30) 1.5 (0.73–2.96)
Not 10/not 10 1.3 (0.40–3.98) 1.7 (0.41–7.46)
1Adjusted for age, age at menarche, age at first full term pregnancy,
menopausal status, first degree family history of breast cancer, and BMI.
doi:10.1371/journal.pone.0029548.t002
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therapy-associated peripheral neuropathy similarly showed no signifi-
cant associations [15]. However, CAG repeat-length polymorphisms
have been associated with male infertility; the common 10-repeat
variant of the CAG repeat was found to be significantly more prevalent
among men with oligospermia [9] and unexplained subfertility [16].
There are two additional reports associating POLG-CAG repeat
variants with cancer risk. Interestingly, a study of CAG repeat
Figure 1. Representative electopherogram of normal CAG (10:10), contraction (6:10) and expansion (10:13) of POLG.
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(74%) wild-type homozygotes and 13 (26%) lacked one or both
wild-type alleles, with the 10/11 variant in 10 patients and the 10/
12, 10/6 and 11/11 variants in one patient each, suggesting that
variants of the DNA POLG1 gene were more frequent in testicular
cancer patients than in healthy men [12]. Another study suggested
that the CAG polymorphism in POLG may be a contributing
factor in the pathogenesis of testicular seminoma [17]. It should be
emphasized, however, that existing studies in of POLG-CAG
repeat variants in cancer compared the frequency of these variants
in tumor tissue to the frequency in either surrounding normal
tissue or blood samples. In contrast, our study evaluated germline
polymorphisms in POLG in both breast cancer cases and in
controls. Results of studies may differ depending on the DNA
source due to additional clonal mutations that can occur in tumor
cells.
This study is the first to investigate the role of CAG repeat
polymorphisms in the nuclear POLG gene, which encodes
mitochondrial DNA polymerase-gamma, in breast cancer risk.
While our findings suggest a possible correlation between CAG
repeat length and risk of breast cancer in AA women, the size of
this genetic study sample was small, as evidenced by reduced
power to demonstrate significant associations of known breast
cancer risk factors such as age at menarche and family history of
breast cancer with cancer risk in this study. Larger, preferably
population-based, studies are needed in order to draw any firm
conclusions about the role of POLG-CAG variants in breast cancer
risk in AA or other populations.
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